Jeffrey Chin
Papers
3
Total Citations
82
H-Index
3
About
Jeffrey Chin is a leading clinical researcher in head and neck oncology, with a primary focus on human papillomavirus-associated oropharyngeal cancer (HPV+ OPC). His work has been instrumental in developing response-adaptive treatment strategies that aim to reduce toxicity without compromising survival. In the landmark OPTIMA II trial (30 citations), Chin demonstrated that combining nivolumab with chemotherapy as neoadjuvant therapy, followed by risk- and response-adapted de-escalated locoregional therapy, is both feasible and effective for HPV+ OPC. He further advanced this paradigm with a 2024 study (45 citations) showing that neoadjuvant nivolumab plus chemotherapy, followed by response-adaptive treatment, can achieve high response rates while potentially sparing patients from aggressive radiation and surgery. Most recently, his 2025 work (7 citations) explores the early dynamics of circulating tumor HPV DNA as a noninvasive biomarker to guide de-escalation decisions. Chin’s contributions are shaping a new standard of care that prioritizes both oncologic efficacy and quality of life, making him a pivotal figure in the movement toward personalized, de-intensified therapy for HPV-driven head and neck cancers.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3